Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Gabriel Tremblay, DBA, MSc, BS, Patrick Daniele, Mike Dolph, MSc BHSc, Timothy J. Bell, Geoffrey Chan, MD, Andrew Brown, PhD, Joseph C Cappelleri, PhD MPH, MS

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137641

Published: 2020

Journal Articles

Patient-Focused Benefits of at-Home Versus in-Clinic Administration of Cancer Therapy: New Considerations for the COVID-19 Era

Karen E. Sandman, PhD, Timothy J. Bell

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137560

Published: 2020

Journal Articles

Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy

Elizabeth Hubscher, Slaven Sikirica, Timothy J. Bell, Andrew Brown, PhD, Verna L Welch, PhD MPH, Alexander Russell-Smith, MSc, Paul G D'Amico, PhDRN,NP

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137425

Published: 2020

Journal Articles

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Youngmin Kwon, BA, Timothy J Bell, MHA, Caitlyn Solem, PhD, Joseph C Cappelleri, PhD MPH, MS, Courtney Johnson, MPH, Helen Bhattacharyya, PhD, Caroline J. Hoang, PhD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 2610.

https://doi.org/10.1182/blood-2019-126672

Published: 2019

Journal Articles

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Thomas W. LeBlanc, MDMA,MHS, Roland B. Walter, MD PhD MS, Loriana Hernandez-Aldama, Kate Sully, PhD, Timothy J Bell, MHA, Chloe Johnson, Francois Peloquin, MSc, Adam Gater, Verna L Welch, PhD MPH, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, MD, Neil Horikoshi, Dawn Maze, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3498.

https://doi.org/10.1182/blood-2019-124660

Published: 2019

Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA

Blood (2019) 134 (Supplement_1): 5852.

https://doi.org/10.1182/blood-2019-122709

Published: 2019

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Chloe Johnson, Timothy J Bell, Kate Sully, PhD, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Francois Peloquin, BS, Adam Gater

Blood (2018) 132 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2018-99-116226

Published: 2018

Journal Articles

Patient-Centered Insights on Living with Acute Myeloid Leukemia and Its Treatments Using Patient Reported Information Shared Via Social Media

Sigrid Rebecca Crawford, MA, Timothy J Bell, Rebecca Rushton, MSc, Lynda Doward, MRes

Blood (2018) 132 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2018-99-112427

Published: 2018

Journal Articles

Treatment in AML and MDS Patients Who Are Ineligible for Intensive Chemotherapy: Using Social Media Intelligence to Capture What Really Matters to Patients

Alison Booth, MSc, Timothy J Bell, Sonia Halhol, MSc, Shiyu Pan, MSc, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Evie Merinopoulou, MSc, Dimitra Lambrelli, PhD, Andrew Cox, PhD

Blood (2018) 132 (Supplement 1): 4826.

https://doi.org/10.1182/blood-2018-99-112827

Published: 2018

Journal Articles

Using Social Media to Highlight Unmet Needs in Patients with AML and MDS Ineligible for Intensive Chemotherapy: A Patient Centered Perspective

Alison Booth, MSc, Timothy J Bell, Sonia Halhol, MSc, Shiyu Pan, MSc, Verna L Welch, PhD MPH, CPEHR, CPHIMS, Evie Merinopoulou, MSc, Dimitra Lambrelli, PhD, Andrew Cox, PhD

Blood (2018) 132 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2018-99-112922

Published: 2018

Journal Articles

Epidemiology of Thrombosis in Aging

Weihong Tang, PhD MS, MD FAHA, Elizabeth J Bell, PhD MPH, Nicholas S Roetker, MPH, Aaron R Folsom, MD MPH, Mary Cushman, MD

Blood (2015) 126 (23): SCI-6.

https://doi.org/10.1182/blood.V126.23.SCI-6.SCI-6

Published: 2015

Journal Articles

The Cytoskeletal Binding Domain of Band 3 Is Required for Multiprotein Complex Formation and Retention during Erythropoiesis

Timothy J Satchwell, PhD, Bethan R Hawley, Amanda J Bell, Maria Leticia Ribeiro, MD PhD, Ashley M Toye, PhD

Blood (2014) 124 (21): 4003.

https://doi.org/10.1182/blood.V124.21.4003.4003

Published: 2014

Journal Articles

Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak–like primary immunodeficiency syndrome

Raffaele Badolato, Alberto Prandini, Sonia Caracciolo, Francesca Colombo, Giovanna Tabellini, Mauro Giacomelli, Maria E. Cantarini, Andrea Pession, Callum J. Bell, Darrell L. Dinwiddie, Neil A. Miller, Shannon L. Hateley, Carol J. Saunders, Lu Zhang, Gary P. Schroth, Alessandro Plebani, Silvia Parolini, Stephen F. Kingsmore

Blood (2012) 119 (13): 3185–3187.

https://doi.org/10.1182/blood-2012-01-404350

Published: 2012

Includes: Supplemental data

Journal Articles

Critical band 3 multiprotein complex interactions establish early during human erythropoiesis

Timothy J. Satchwell, Amanda J. Bell, Stephanie Pellegrin, Sabine Kupzig, Kay Ridgwell, Geoff Daniels, David J. Anstee, Emile van den Akker, Ashley M. Toye

Blood (2011) 118 (1): 182–191.

https://doi.org/10.1182/blood-2010-10-314187

Published: 2011

Includes: Supplemental data

Journal Articles

Cross-recognition of HLA DR4 alloantigen by virus-specific CD8 + T cells: a new paradigm for self-/nonself-recognition

Michael Rist, Corey Smith, Melissa J. Bell, Scott R. Burrows, Rajiv Khanna

Blood (2009) 114 (11): 2244–2253.

https://doi.org/10.1182/blood-2009-05-222596

Published: 2009

Journal Articles

Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia

P Moss, G Gillespie, P Frodsham, J Bell, H Reyburn

Blood (1996) 87 (8): 3297–3306.

https://doi.org/10.1182/blood.V87.8.3297.bloodjournal8783297

Published: 1996

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Patient-Focused Benefits of at-Home Versus in-Clinic Administration of Cancer Therapy: New Considerations for the COVID-19 Era

Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy

Quality-Adjusted Survival for Low-Dose Cytarabine (LDAC) Versus Glasdegib+LDAC Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Not Candidates for Intensive Chemotherapy: A Q-TWiST Analysis

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

A Patient-Centred Approach to Understanding the Trade-Offs Associated with Treatment Decision Making in Hematological Cancers with Short Life Expectancy

Patient-Centered Insights on Living with Acute Myeloid Leukemia and Its Treatments Using Patient Reported Information Shared Via Social Media

Treatment in AML and MDS Patients Who Are Ineligible for Intensive Chemotherapy: Using Social Media Intelligence to Capture What Really Matters to Patients

Using Social Media to Highlight Unmet Needs in Patients with AML and MDS Ineligible for Intensive Chemotherapy: A Patient Centered Perspective

Epidemiology of Thrombosis in Aging

The Cytoskeletal Binding Domain of Band 3 Is Required for Multiprotein Complex Formation and Retention during Erythropoiesis

Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlak–like primary immunodeficiency syndrome

Critical band 3 multiprotein complex interactions establish early during human erythropoiesis

Cross-recognition of HLA DR4 alloantigen by virus-specific CD8 + T cells: a new paradigm for self-/nonself-recognition

Clonal populations of CD4+ and CD8+ T cells in patients with multiple myeloma and paraproteinemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only